Paredes R - Search Results

1

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.

Sachse M, Tenorio R, Fernández de Castro I, Muñoz-Basagoiti J, Perez-Zsolt D, Raïch-Regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C. Sachse M, et al. Among authors: paredes r. Antiviral Res. 2022 Apr;200:105270. doi: 10.1016/j.antiviral.2022.105270. Epub 2022 Feb 26. Antiviral Res. 2022. PMID: 35231500 Free PMC article.

2

The potential role of interleukin-2 in patients with HIV infection.

Paredes R, López Benaldo de Quirós JC, Fernández-Cruz E, Clotet B, Lane HC. Paredes R, et al. AIDS Rev. 2002 Jan-Mar;4(1):36-40. AIDS Rev. 2002. PMID: 11998783 Review.

3

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B. Negredo E, et al. Among authors: paredes r. AIDS. 2002 Jul 5;16(10):1383-9. doi: 10.1097/00002030-200207050-00010. AIDS. 2002. PMID: 12131215 Clinical Trial.

4

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B. Paredes R, et al. AIDS. 2003;17 Suppl 4:S85-96. doi: 10.1097/00002030-200317004-00010. AIDS. 2003. PMID: 15080184 Review. No abstract available.

5

[Duration of antiretroviral combinations].

Paredes R, Clotet B. Paredes R, et al. Med Clin (Barc). 2004 May 15;122(18):696-7. doi: 10.1016/s0025-7753(04)74359-6. Med Clin (Barc). 2004. PMID: 15171830 Spanish. No abstract available.

6

Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.

Negredo E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, Fumoz CR, Ruiz L, Abril V, Rodriguez de Castro E, Ochoa C, Martinez-Picado J, Montaner J, Rey-Joly C, Clotet B; Swatch Study Team. Negredo E, et al. Among authors: paredes r. Antivir Ther. 2004 Dec;9(6):889-93. Antivir Ther. 2004. PMID: 15651747 Clinical Trial.

7

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Negredo E, et al. Among authors: paredes r. Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15. Clin Infect Dis. 2005. PMID: 16107993 Clinical Trial.

8

Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.

Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, Cabrera C, Romeu J, Bofill M, Clotet B, Martinez-Picado J. Darwich L, et al. Among authors: paredes r. AIDS Res Hum Retroviruses. 2008 May;24(5):725-32. doi: 10.1089/aid.2007.0255. AIDS Res Hum Retroviruses. 2008. PMID: 18462084

9

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Dalmau J, Puertas MC, Azuara M, Mariño A, Frahm N, Mothe B, Izquierdo-Useros N, Buzón MJ, Paredes R, Matas L, Allen TM, Brander C, Rodrigo C, Clotet B, Martinez-Picado J. Dalmau J, et al. Among authors: paredes r. Clin Infect Dis. 2009 Jan 15;48(2):229-38. doi: 10.1086/595704. Clin Infect Dis. 2009. PMID: 19093810 Free PMC article.

10

Clinical approach to drug resistance interpretation: expert advice.

Clotet B, Paredes R. Clotet B, et al. Among authors: paredes r. Curr Opin HIV AIDS. 2007 Mar;2(2):145-9. doi: 10.1097/COH.0b013e32801470f6. Curr Opin HIV AIDS. 2007. PMID: 19372880

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

742 results

Search Page

Filters